INSANE: Pharmaceutical industry - The Real Truth

The FTC and seven states allege Martin Shkreli traded stocks of at least 60 drug companies despite a lifetime pharma ban and want him held in contempt.

AstraZeneca has entered a collaboration with insitro to explore new treatment options for challenging liver and heart diseases. The partnership involves a $40 million upfront payment and potential milestones totaling approximately $1.46 billion. Insitro will utilize its AI platform to identify biological drivers for metabolic dysfunction-associated steatohepatitis and cardiomyopathies. Following…

Martin Shkreli’s 2022 release conditions bar him from participating in the pharmaceutical industry, including ownership stakes or business decisions

Kiran Mazumdar-Shaw emphasized the importance of building an innovation-driven pharmaceutical industry in India. She highlighted the need for continued investment in research and regulatory reforms to enhance drug development. The industry must focus on maintaining high-quality standards as it seeks to innovate. Closer cooperation between industry and regulators can help…

India's CRDMO sector is on the brink of expansion, backed by solid partnerships with major pharmaceutical players and comprehensive capabilities. Jefferies emphasizes the critical role of specialized manufacturing skills and a strong project pipeline for achieving success. With Divi's Laboratories and Sai Life Sciences excelling in these domains, there is…

US Ambassador Sergio Gor emphasized the strengthening collaboration between India and America in defense and healthcare sectors. During an event in Kolkata, he mentioned recent military exercises involving Indian and American forces. Gor also highlighted significant investments in information technology and shared trust in India's pharmaceutical industry. The US is…

Speaking at the India-UK JETCO Business Plenary on Monday, Goyal highlighted the complementary nature of the two economies and stressed the need to strengthen economic partnerships to unlock new growth opportunities.

Indian pharma and chemical companies at CPHI Milan say the China+1 opportunity is real, but a “missing middle” in the MSME ecosystem, marked by financing gaps, limited scale and technology constraints, is holding back export growth.

Inventiva, Larimar Therapeutics, and Ascentage Pharma face key drug-development milestones, with analysts assigning Buy ratings and triple-digit upside price targets to all three biotech stocks.